An increasing proportion of the population has acquired immunity through COVID-19
vaccination and previous SARS-CoV-2 infection, ie, hybrid immunity, possibly affecting the …

On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

Given the emergence of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants and the roll-out
of booster COVID-19 vaccination, evidence is needed on protection conferred by primary …

Background Elucidating viral dynamics within the host is important for designing public
health measures against SARS-CoV-2, particularly during the early stages of infection when …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections in
vaccinated individuals and reinfections in previously infected individuals have become …

The massive and rapid transmission of SARS-CoV-2 has led to the emergence of several
viral variants of concern (VOCs), with the most recent one, B. 1.1. 529 (Omicron), which …

Abstract The SARS-CoV-2 B. 1.1. 529/Omicron variant was first characterized in South Africa
and was swiftly designated a variant of concern 1. Of great concern is its high number of …

Emerging in November 2021, the SARS-CoV-2 Omicron variant of concern exhibited
marked immune evasion resulting in reduced vaccine effectiveness against SARS-CoV-2 …

New genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
constantly emerge through unmitigated spread of the virus in the ongoing Coronavirus …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …